Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14712598.2020.1798399 http://scihub22266oqcxt.onion/10.1080/14712598.2020.1798399 32700604!ä!32700604 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32700604&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Opin+Biol+Ther 2020 ; 20 (9): 1025-1031 Nephropedia Template TP {{tp|p=32700604|t=2020. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications |pdf=|usr=}}{{32700604}} gab.com Text Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications JO: Expert Opin Biol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32700604 #FOAvip INTRODUCTION: The globally rampant SARS CoV-2 pandemic requires novel medical strategies to control the severity of disease and death due to complications. Of the 15-20% patients that develop pulmonary symptoms, a sub-set develops an acute respiratory distress syndrome (ARDS) rapidly progressing into a critical condition. Marked elevation of cytokines/chemokines is observed with elevation of additional markers of inflammation, coagulation, and organ damage such as CRP, D-dimer, LDH, Ferritin and Troponin-I. This hyperinflammation leads to worsening of oxygen saturation due to pulmonary infiltration and exudation, organ damage, and dysfunction of coagulation pathway and may lead to multi-organ failure. AREAS COVERED: The role of anti-inflammatory monoclonal antibodies such as Itolizumab, in cytokine storm. EXPERT OPINION: Itolizumab, an anti-CD6 humanized IgG1 mAb, binds to domain-1 of CD-6 that is responsible for priming, activation, and differentiation of T-cells. Itolizumab significantly reduces T-cell proliferation along with substantial downregulation of the production of cytokines/chemokines. Approved for moderate to severe chronic plaque psoriasis in 2013 it is currently being studied for addressing COVID-19 related cytokine storm and its complications. This article reviews its use in COVID-19 infections; its dose, administration protocol, contra-indications, and safety in treating moderate-to-severe ARDS by preventing and treating the cytokine storm and its complications. Twit Text FOAVip Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications ????Expert Opin Biol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32700604 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32700604 #FOAvip English Wikipedia <ref>{{Cite pmid|32700604}}</ref> Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications #MMPMID32700604 Loganathan S; Athalye SN; Joshi SR Expert Opin Biol Ther 2020[Sep]; 20 (9): 1025-1031 PMID32700604show ga INTRODUCTION: The globally rampant SARS CoV-2 pandemic requires novel medical strategies to control the severity of disease and death due to complications. Of the 15-20% patients that develop pulmonary symptoms, a sub-set develops an acute respiratory distress syndrome (ARDS) rapidly progressing into a critical condition. Marked elevation of cytokines/chemokines is observed with elevation of additional markers of inflammation, coagulation, and organ damage such as CRP, D-dimer, LDH, Ferritin and Troponin-I. This hyperinflammation leads to worsening of oxygen saturation due to pulmonary infiltration and exudation, organ damage, and dysfunction of coagulation pathway and may lead to multi-organ failure. AREAS COVERED: The role of anti-inflammatory monoclonal antibodies such as Itolizumab, in cytokine storm. EXPERT OPINION: Itolizumab, an anti-CD6 humanized IgG1 mAb, binds to domain-1 of CD-6 that is responsible for priming, activation, and differentiation of T-cells. Itolizumab significantly reduces T-cell proliferation along with substantial downregulation of the production of cytokines/chemokines. Approved for moderate to severe chronic plaque psoriasis in 2013 it is currently being studied for addressing COVID-19 related cytokine storm and its complications. This article reviews its use in COVID-19 infections; its dose, administration protocol, contra-indications, and safety in treating moderate-to-severe ARDS by preventing and treating the cytokine storm and its complications. |*Betacoronavirus[MESH] |Antibodies, Monoclonal, Humanized/pharmacology/*therapeutic use[MESH] |Antigens, CD/*immunology[MESH] |Antigens, Differentiation, T-Lymphocyte/*immunology[MESH] |COVID-19[MESH] |Cell Differentiation/drug effects/physiology[MESH] |Cell Proliferation/drug effects/physiology[MESH] |Coronavirus Infections/*drug therapy/*immunology[MESH] |Cytokines/antagonists & inhibitors/immunology[MESH] |Humans[MESH] |Lymphocyte Activation/drug effects/physiology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/*immunology[MESH] |SARS-CoV-2[MESH] |T-Lymphocytes/drug effects/immunology[MESH]Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment (epmc).pdf DeepDyve Pubget Overpricing